Stay updated on Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial

Sign up to get notified when there's something new on the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    Added a note that PubMed publications are auto-filled and may not be about the study, updated the revision to v3.3.2, and removed the older PubMed note and revision v3.2.0—To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-24T16:53:01.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The page no longer displays a government funding lapse disclaimer; the study details are unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-17T15:00:12.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    No substantive content changes to the study details page were detected; the differences appear limited to metadata and formatting, leaving core study information unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T01:29:40.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    - Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.
    Difference
    2%
    Check dated 2025-10-05T10:20:54.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    Updated page to revision v3.1.0 and added a new academic citation (authors, title, journal, date, DOI) for a study on mirvetuximab soravtansine in FRα-high platinum-resistant ovarian cancer.
    Difference
    2%
    Check dated 2025-09-28T03:20:34.000Z thumbnail image
  9. Check
    94 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.
    Difference
    0.1%
    Check dated 2025-09-13T17:43:45.000Z thumbnail image

Stay in the know with updates to Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page.